For example, the overall response rate of NSCLC patients (with PD-L1 Tumor Proportion Score (TPS) ≥ 50%, defined as ≥ 50% of tumor cells showing PD-L1 positivity by IHC) to pembrolizumab is 44.8%, whereas that to chemotherapy is 27.8%16. This evidence concerns the gene CD274 and non-small cell lung carcinoma.